Clinical Trial

Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy

Study acronym: EMPACT
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the safety and effectiveness of Enavogliflozin 0.3 mg, an SGLT2 inhibitor, in patients with amyloid cardiomyopathy. Participants will take both the study drug and a placebo in two separate periods, with a wash-out period in between. The goal is to determine whether Enavogliflozin is safe and effective for treating amyloid cardiomyopathy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-20.
Status change: Not Yet Recruiting → Recruiting 2026-06-16
Trial Details
NCT Number NCT07240844
Lead Sponsor Seoul St. Mary's Hospital
Collaborators: Samsung Medical Center
Conditions Amyloid Cardiomyopathy
Enrollment 68 participants
Start Date 2026-01-06
Primary Completion 2027-04-29 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-18